Status:
COMPLETED
Swallowing Therapy With the Assistance of a Mobile Health Device in Head and Neck Cancer Patients: a Pan-Alberta Study
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
Alberta Cancer Foundation
Conditions:
Dysphagia
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Dysphagia affects 22% of those over the age of 50, which equates to 250 million people worldwide and 360,000 in Alberta. At high risk are survivors of head and neck cancer (70%). Difficulties with swa...
Detailed Description
Background Dysphagia affects 22% of those over the age of 50 \[1\], which equates to 250 million people worldwide and 360,000 in Alberta \[2\]. At high risk are survivors of head and neck cancer (70%)...
Eligibility Criteria
Inclusion
- prior diagnosis of oropharyngeal dysphagia secondary to treatment for squamous cell carcinoma (OPSCC)
- 3 months or later post-surgery or post-(chemo)radiation therapy
- received treatment for head and neck cancer (e.g., +/-surgery, +/-radiation therapy, +/- chemotherapy)
- attending speech-language pathologist has confirmed from a Modified Barium Swallow (MBS) assessment or Fiberoptic Endoscopic Evaluation of Swallowing (FEES) that the patient is a candidate for the effortful swallow and/or the Mendelsohn maneuver therapy.
Exclusion
- have a history of cognitive delay (patient or SLP reported)
- have a history of stroke or traumatic brain injury (patient or SLP reported)
- cannot reliably navigate the Mobili-T system after the training session
- attending SLP confirms planned swallowing exercises or procedures to address dysphagia like esophageal dilation
- have an implanted electronic device of any kind, including cardiac pacemakers or similar assistive devices, electronic infusion pumps, and implanted stimulators
- have irritated skin or skin with open wounds under the chin
- have an allergy to silver
- have a beard or not willing to shave or partially shave
- unable to travel to Edmonton 3 times during a 3 month period
Key Trial Info
Start Date :
October 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04698499
Start Date
October 27 2021
End Date
October 1 2023
Last Update
February 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada